St. Jude Care & Treatment

Menu

Close

Recruiting

PBTC49: Phase 1 Trial of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

About this study

This is a clinical research study for children and young adults with brain cancer that has grown or come back after standard therapy.

The drug in this study is called savolitinib (volitinib). It is considered an experimental drug that has been tested in adults with advanced solid tumors. There is scientific reason to believe it may work against brain tumors. However, we have not yet found the safe dose for children or proven that the drug works for brain tumors. This trial is being conducted to see if savolitinib is safe and tolerable in children with brain tumors.

Eligibility overview

  • Recurrent, refractory. or progressive medulloblastoma, high-grade glioma (HGG), or diffuse intrinsic pontine glioma (DIPG)
  • Evidence of genetic activation of the MET pathway (expansion co-hort)
  • Between 5 years old and 21 years old

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

Study goal:

 To see if savolitinib is safe and tolerable in children with brain tumors

Diagnosis:

Medulloblastoma, high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG)

Age:

Between 5 years old and 21 years old

Clinical trials categories:

Medulloblastoma Childhood Cancer Diffuse Intrinsic Pontine Glioma (DIPG) High-Grade Glioma Brain Tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more